Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | PTGFR | P43088 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632019 | 0.85 | CES2 (0.42) | FFAR1FFAR4KMT2A | |
| SCHEMBL21632180 | 0.84 | MDM2 (0.38) | FFAR1FFAR4PTGFRKMT2A | |
| SCHEMBL21656308 | 0.83 | FFAR1 (0.36) | FFAR1FFAR4KMT2A | |
| SCHEMBL20534476 | 0.81 | FFAR1 (0.44) | FFAR1FFAR4PTGFRKMT2ACTSA | |
| SCHEMBL21708588 | 0.81 | FFAR1 (0.34) | FFAR1FFAR4PTGFRKMT2A | |
| SCHEMBL21632003 | 0.79 | ALDH1A1 (0.43) | FFAR1FFAR4KMT2ATSHRMEN1 | |
| SCHEMBL21631904 | 0.77 | PTGFR (0.46) | FFAR1FFAR4PTGFRKMT2ACTSA | |
| SCHEMBL21632071 | 0.77 | CES2 (0.42) | FFAR1FFAR4PTGFRKMT2A | |
| SCHEMBL21632189 | 0.73 | CCR1 (0.43) | FFAR1FFAR4KMT2ATSHRMEN1 | |
| SCHEMBL12493400 | 0.71 | CTSA (0.43) | FFAR1FFAR4CTSAMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | FFAR1 781/4885FFAR4 185/4885PTGFR 1050/4885 |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, ARG2, GOT2 | FFAR1 1059/4885FFAR4 247/4885PTGFR 1184/4885 |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | AADAC, ARG2, GOT2 | FFAR1 1059/4885FFAR4 247/4885PTGFR 1184/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | FFAR1 781/4885FFAR4 185/4885PTGFR 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.